Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of the therapeutic use of 177Lu-PSMA-617 in metastatic castrate-resistant prostate cancer. However, PSMA is also expressed in the neovasculature of other solid tumors, such as lung and renal cancer, making the theranostic potential of 177Lu-PSMA-617 worth exploring in this setting. Here is such a case of an 83-year-old man with advanced non-small cell lung cancer where the theranostic potential of 177Lu-PSMA-617 was explored using dosimetric analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005816 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review.
Front Oncol
February 2025
Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Anaplastic lymphoma kinase (ALK) inhibitors have shown efficacy in treating ALK-positive advanced non-small cell lung cancer (NSCLC) patients. However, the effectiveness of ensartinib neoadjuvant therapy remains ambiguous. Herein, we reported that preoperative systemic treatment with the ALK inhibitor ensartinib can be beneficial for treating initially inoperable tumors.
View Article and Find Full Text PDFAn Exceptional Case of Garcin Syndrome Mimicking Bell's Palsy in Advanced Non-Small Cell Lung Carcinoma.
Indian J Otolaryngol Head Neck Surg
February 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Cheras, Malaysia.
Garcin syndrome is an exceptional clinical condition characterized by progressive multiple ipsilateral cranial nerve involvement which is caused by malignant osteoclastic lesion at skull base. We report a rare case of Garcin syndrome which was misdiagnosed as Bell's palsy. A 69-year-old lady, presented with generalized headache and right facial nerve palsy in which progressively worsened even after treatment with corticosteroid.
View Article and Find Full Text PDFA Mini-Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms.
Curr Pharm Des
March 2025
Pharmacy Department, Tishk International University, Erbil, Iraq.
Background: An essential component of cell development, proliferation, and survival is the transmembrane receptor known as the epidermal growth factor receptor (EGFR). Dysregulated EGFR signalling is an appealing pathway that has been linked to the genesis and progression of several cancer types. EGFR tyrosine kinase inhibitors (TKIs) are targeted drugs that show promise in the fight against cancer.
View Article and Find Full Text PDFThe value of whole-body MRI instead of only brain MRI in addition to 18 F-FDG PET/CT in the staging of advanced non-small-cell lung cancer.
Cancer Imaging
March 2025
Radiology, Department of Surgical Sciences, Uppsala University, Uppsala University Hospital, entry 70, 1st floor, Uppsala, 751 85, Sweden.
Background: Non-small cell lung cancer (NSCLC) is a common neoplasm with poor prognosis in advanced stages. The clinical work-up in patients with locally advanced NSCLC mostly includes F-fluorodeoxyglucose positron emission tomography computed tomography (F-FDG PET/CT) because of its high sensitivity for malignant lesion detection; however, specificity is lower. Diverging results exist whether whole-body MRI (WB-MRI) improves the staging accuracy in advanced lung cancer.
View Article and Find Full Text PDFCombined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function.
Sci Rep
March 2025
Cancer Center, Department of Thoracic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Lung cancer is a major cause of cancer-related deaths globally. Targeted therapies, specifically attacking cancer cells based on genetic mutations, offer promising alternatives. ALK (anaplastic lymphoma kinase) fusions result in aberrant proteins that drive cancer growth.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!